Brazilian pediatrician Monica Levi, one of the volunteers who received COVID-19, works at the Specialized Clinic of Infectious and Parasitic Diseases and Immunization (CEDIPI), in Sao Paulo, Brazil. , on 24 July 2020. The doctor was one of 5,000 volunteers participating in the Phase 3 trial in Brazil – the last time before homogenization – of the ChAdOx1 nCoV-19 vaccine, jointly run by Oxford University. development with the British pharmaceutical company AstraZeneca.
Nelson Almeida | AFP | beautiful images
British pharmaceutical giant AstraZeneca said on Thursday that it expects vaccine data to be available this year as it reports strong third-quarter sales.
“Results from end-stage trials are projected later this year, depending on infection rates in the community where clinical trials are being conducted. Data readings will be submitted for these trials. regulatory body and publishing in peer-reviewed scientific journals, ”said AstraZeneca. it gave its results.
The manufacturer of the drug said global product sales, excluding payments from cooperation, rose 7% to $ 6.52 billion in the three months ending September 30, on the basis of The monetary department is unchanged. That is ahead of the $ 6.5 billion consensus compiled by the company.
AstraZeneca’s chief executive, Pascal Soriot, said the results showed the drug maker “made an encouraging step forward this quarter, despite the constant disruption from the Covid-19 pandemic.” The company has maintained guidance for the whole year.
A lot of hope has been placed on AstraZeneca this year as they are developing a coronavirus vaccine in partnership with Oxford University. The vaccine candidate, technically named AZD1222, is in end-stage clinical trials going on in the UK, Brazil, South Africa, and the US and attracts around 23,000 participants.
Trials in the UK and the US recently had to be halted due to illnesses of unknown etiology but two participants were given a green light by the regulators to continue when these were given. is not related to the experimental vaccine.
Last Monday, the drugmaker released an update on the vaccine’s progression, saying it produced a similar immune response in older and younger adults.
The news has spurred hopes that a vaccine could be offered later this year, even though the drug manufacturer missed its target of delivering 30 million doses (part of a 100 million dose deal has already been agreement with the UK government in May) Covid-19 vaccine arrived in the UK in September.
In June, several European countries signed an agreement with AstraZeneca for up to 400 million doses of the vaccine with the first batch of doses scheduled for later this year.
On Wednesday, the head of Britain’s vaccine task force, or the procurement program, admitted that the September 30 million dose target was not met, instead it was estimated that Britain would receive 4 million. dose at the end of the year, Reuters reported, and 100 million doses “in the first half of next year.”